Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


About Seragen

Developer of a new class of therapeutic products known as fusion toxins. These products consist of fragments of toxin fused to ligands that target specific cell surface receptors. These fused molecules are designed to (1) bind to specific receptors which are present on the surface of disease-causing or diseased cells, (2) penetrate the targeted cells and eliminate their ability to spread disease. The fusion toxins were developed using proprietary technology and have potential applications in human diseases including diseases that are either incurable or diseases for which existing therapies are of limited effect. These include cancers and autoimmune diseases such as rheumatoid arthritis and recent onset type-1 diabetes, as well as other conditions and diseases involving the immune system.

Seragen Headquarter Location

97 South Street

Hopkinton, Massachusetts, 01748,

United States


Latest Seragen News

How biotech startup Seragen is reworking infertility treatments with regenerative therapies

Dec 3, 2020

Chennai-based biotech startup Seragen is developing therapies to treat infertility in India holistically. It claims to deliver safer and better results.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Seragen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Seragen is included in 1 Expert Collection, including Diabetes.



1,750 items

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.